Document:

Form of Restricted Stock Units Agreement-Employee(2002 Equity Compensation Plan)

 Exhibit 10.3 
 Form of DaVita Inc. 
 Restricted Stock Units Award 
 under the DaVita Inc. 2002 Equity Compensation Plan 
 Name: 
 Address: 
 SSN: 
 In recognition of your continuing contributions toward making DaVita the Greatest Dialysis Company the World has ever seen, and as a reward for your hard work and
commitment to living our Mission and our Values, you have been granted this award (the “Award”) of restricted stock units (“Restricted Stock Units” or “Units”) under DaVita’s 2002 Equity Compensation Plan (the
“Plan”). This award represents your right to receive shares of common stock of DaVita Inc. (the “Company”), subject to your fulfillment of the vesting conditions set forth in this agreement (the “Agreement”).

 The terms of your Award are as set forth in this Agreement and in the Plan. The Plan is incorporated into this Agreement by reference, which means that
this Agreement is limited by and subject to the terms of the Plan. In the event of a conflict between the terms of this Agreement and the terms of the Plan, the terms of the Plan will control. Capitalized terms that are used here but that are not
defined in this Agreement have the meanings given to them in the Plan. The most important terms of the Award are summarized as follows: 
  

			
	1. Award Date:	  	
		
	2. Number of Units:	  	
		
	3. Vesting Schedule:	  	
		  	
		  	
		  	
		  	
		  	
		  	

 The terms set forth above, together with the terms and conditions attached, constitute one agreement.

 Note: Please mark and initial any correction to the Name, SSN and/or Address shown on this page before returning a signed copy of this agreement to
the Stock Plan Administrator 

 4. Conversion of Restricted Stock Units and Stock Issuance. Upon each vesting date of the Award (each, a
“Vesting Date”), one share of Common Stock will become issuable to you for each Restricted Stock Unit that vests on such Vesting Date (the “Shares”). After the Vesting Date, the Company will issue the Shares to you, after
reducing the Shares by a number of shares (if any) that are sold to satisfy your tax withholding obligations. No fractional shares will be issued under this Agreement, even though such fractions may result if a portion of a share must be sold to pay
your withholding taxes. 
 5. Termination of Employment. You must be an employee of the Company on a Vesting Date in order to receive the Shares then
vesting. Thus, Restricted Stock Units will not continue to vest if your employment terminates for any reason, including in the event you die, become disabled, retire, or change status to that of an independent contractor. In those circumstances, you
will forfeit your right to any Restricted Stock Units that would otherwise vest after the date on which your employment is terminated. 
 6. Right to
Shares. You will not have any right to the Shares subject to your Award until they are actually issued to you. 
 7. Taxes. 

 (a) Generally. You are ultimately liable and responsible for all taxes owed in connection with the Award,
regardless of any action the Company or any of its Subsidiaries takes with respect to any tax withholding obligations that arise in connection with the Award. Neither the Company nor any of its Subsidiaries makes any representation or undertaking
regarding the treatment of any tax withholding in connection with the grant or vesting of the Award or the subsequent sale of Shares issuable pursuant to the Award. The Company and its Subsidiaries do not commit and are under no obligation to
structure the Award to reduce or eliminate your tax liability. As a condition and term of this Award, no election under 83(b) of the United States Internal Revenue Code may be made by you or any other person with respect to all or any portion of the
Award. 
 (b) Payment of Withholding Taxes. Prior to any event in connection with the Award (e.g., vesting) that the
Company determines may result in any domestic or foreign tax withholding obligation, whether national, federal, state or local, including any social tax obligation (the “Tax Withholding Obligation”), you must arrange for the satisfaction
of the minimum amount of such Tax Withholding Obligation in a manner acceptable to the Company. You may choose to satisfy your tax obligation in either of the following manners: 
 (i) By Sale of Shares. Unless you choose to satisfy the Tax Withholding Obligation by some other means in accordance
with clause (ii) below, your acceptance of this Award constitutes your instruction and authorization to the Company and any brokerage firm determined acceptable to the Company for such purpose to withhold or sell on your behalf a whole number
of Shares from those Shares issuable to you as the Company determines to be appropriate to generate cash proceeds sufficient to satisfy the Tax Withholding Obligation. Such Shares will be sold on the day the tax Withholding Obligation arises
(e.g., a Vesting Date) or as soon thereafter as practicable. You will be responsible for all broker’s fees and other costs of sale, and you agree to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating
to any such sale. To the extent the proceeds of such sale exceed your Tax Withholding Obligation, the Company agrees to pay such excess in cash to you through payroll or otherwise as soon as practicable. You acknowledge that the Company or its
designee is under no obligation to arrange for such sale at any particular price, and that the proceeds of any such sale may not be sufficient to satisfy your Tax Withholding Obligation. Accordingly, you agree to pay to the Company or any of its
Subsidiaries as soon as practicable, including through additional payroll withholding, any amount of Tax Withholding Obligation that is not satisfied by the sale of Shares described above. 
 (ii) By Check, Wire Transfer or Other Means. At any time not less than ten (10) business days before any Tax
Withholding Obligation arises (e.g., a Vesting Date), you may notify the Company of your intent to make a separate cash payment to satisfy your Tax Withholding Obligation. If you elect to satisfy your Tax Withholding Obligation in this manner, you
will be asked to remit to the Company an amount that the Company determines is sufficient to satisfy the Tax Withholding Obligation within ten (10) business days after the Vesting Date by (a) delivery of a certified check payable to the
Company, attn: Dan Chandler, Stock Plan Administrator, P.O Box 2076, Tacoma, Washington 98401-2076, or such other address as the Company may from time to time direct, (b) wire transfer to such account as the Company may direct, or (c) such
other means as the Company may establish or permit. If you do not remit this amount to the Company within twenty (20) business days after the Vesting Date, the Company reserves the right to satisfy your Tax Withholding Obligation in the manner
set out under paragraph (i) above in its sole discretion. 

 (c) Right to Retain Shares. The Company will not be able to issue any Shares to you until you
satisfy the Tax Withholding Obligation. 
 8. Assignment. Your interest in this Award may not be assigned or alienated, whether voluntarily or
involuntarily. 
 9. Amendments. This Award may be amended only by means of a written document signed by both you and the Company.
Notwithstanding the foregoing, if there is a meaningful reduction, determined in the Company’s sole discretion, in your duties and responsibilities and the level of your regular cash compensation for an extended or indefinite period of time,
the Company reserves the right to unilaterally revoke some or all of the unvested portion of the Award. 
 10. Change of Control of the Company. Under
certain circumstances, if the Company is sold, your entire Award will vest immediately. The specific rules regarding the circumstances in which full vesting would occur are contained in an exhibit to this Agreement. 
 11. Non-Competition/Non-Solicitation/Non-Disclosure 
 (a) You acknowledge and recognize the highly competitive nature of the business of the Company and accordingly agree that while you are an employee of the Company and for the one-year period following termination of such relationship, you
will not (i) engage in or become an employee, director, principal or shareholder of, consultant to or equity participant in, any person, firm, partnership in, any person, firm, partnership, joint venture, association, corporation or other
business organization, entity, or enterprise other than the Company that engages in activities that are in competition with the Company in the United States; (ii) directly or indirectly, own, manage, control, operate, invest in, acquire an
interest in, or otherwise engage in, act for, or act on behalf of any person firm, partnership, joint venture, association, corporation or other business organization, entity, or enterprise other than the Company that engages in activities that are
in competition with the Company; (iii) be an officer, director, consultant, partner, employee, creditor, agent, trustee, independent contractor, or advisor on a paid or unpaid basis of any person, firm, partnership, joint venture, association,
corporation or other business organization, entity, or enterprise that has been a supplier to or client of the Company; (iv) be an officer, director, consultant, partner, owner, employee, creditor, agent, trustee, independent contractor, or
advisor on a paid or unpaid basis of any physician group or physician partners who provide nephrology-related services; (v) (x) directly or indirectly induce any employee of the Company, its affiliates or its subsidiaries or any physician
with privileges at a dialysis facility owned by the Company, its affiliates or its subsidiaries to (A) engage in any activity that you have agreed to refrain from pursuant to (i)-(iv) above or (B) terminate his or her relationship
with the Company or any of its affiliates or subsidiaries or (y) directly or indirectly employ, or offer employment to or other similar arrangement with, any person who is or was during the period of your employment or consulting or advisory
relationship with the Company, or was beforehand, employed or engaged by the Company, its affiliates or subsidiaries, including but not limited to a medical director of a dialysis facility owned or operated by the Company, its subsidiaries or
affiliates, or a physician with admitting privileges at a dialysis facility owned, operated or managed by Company, or one of its affiliates or subsidiaries, or (vi) take any action that results, or might reasonably result in any of the
foregoing. 
 (b) In addition, you agree not to disclose or use for your own benefit or purposes or for the benefit or purposes of any
person, firm, partnership, joint venture, association, corporation or other business organization, entity or enterprise other than the Company and any of its subsidiaries or affiliates, any trade secrets, information, data, or other confidential
information relating to customers, development, programs, costs, marketing, trading, investment, sales activities, promotion, credit and financial data, financing methods, plans, or the business and affairs of the Company (“Information”);
provided, however, the foregoing shall not apply to (i) Information which is not unique to the Company, or (ii) Information which is generally known to the industry or the public other than as a result of your breach of this covenant, or
(iii) disclosure that is required by any applicable law, rule or regulation. If you receive such a request to produce Information in your possession, you shall provide Company reasonable advance notice, in writing, prior to producing said
Information, so as to give Company reasonable time to object to your producing said Information. You also agree that you will not become employed by or enter into service with any person, firm, partnership, joint venture, association, corporation or
other business organization, entity or enterprise other than the Company and any of its subsidiaries or affiliates in which you will be obligated to disclose or use any Information, or where such disclosure would be inevitable because of the nature
of the position. 
 (c) If, at any time within (a) the Term of this Agreement, or (b) one (1) year after termination of
employment for any reason, whichever is the latest, you (i) breach the non-competition provision of Section 11(a), (ii) breach the non-solicitation provision of Section 11(a), (iii) breach the non-disclosure provision of
Section 11(b), (iv) are convicted of a felony, (v) have been adjudicated by a court of competent jurisdiction of having committed an act of fraud or dishonesty resulting or intending 

 
to result directly or indirectly in personal enrichment at the expense of the Company, or (vi) are excluded from participating in any federal health
care program, then (1) this Agreement shall terminate effective on the date on which you enter into such activity, and (2) any consideration received by you as a result of this Award under this Agreement shall be paid by you to the
Company. 
 12. Execution of Award Agreement. This agreement may be considered null and void at the discretion of the Company if a signed copy is not
returned to the Stock Plan Administrator for the Company by NO LATER THAN                         . 
 In Witness Whereof, the Company and the recipient have executed this Agreement as of the date first written above. 
  

									
	 Recipient
	 	 	 	 Leadership
 (Executive, V.P., etc.)
	 	 	 	 Company

					
	  
  
 Printed Name
	 		 	  
  
 Printed Name
	 		 	  
  
 Printed Name

					
	  
 Signature
	 		 	  
 Signature
	 		 	  
 Signature

					
	  
 Title
	 		 	  
 Title
	 		 	  
 Title

					
	  
 Division/Department
	 		 	  
 Division/Department
	 		 	  
 Division/Department

 EXHIBIT 
 Events Causing Full Vesting Awards 
 In the event that either (i) in connection with a “Change of
Control” (defined below), the “Acquiror” (defined below) fails to assume, convert or replace this Award, or (ii) your employment is terminated within the twenty-four (24) month period following a Change of Control by the
Company (or the Acquiror) other than for “Cause” (defined below) or, if applicable, by you in accordance with the termination for “Good Reason” provisions of your employment agreement, if any, then, in any such case, this Award
shall automatically vest and become immediately exerciseable in its entirety, such vesting to be effective as of immediately prior to the effective date of the Change of Control in the case of (i), and as of the date of termination of your
employment in the case of (ii). 
 Change of Control will mean: 
 (i) any transaction or series of transactions in which any person or group (within the meaning of Rule 13d-5 under the Exchange Act and Sections 13(d) and 14(d) under the Exchange Act) becomes the direct or indirect “beneficial
owner” (as defined in Rule 13d-3 under the Exchange Act), by way of a stock issuance, tender offer, merger, consolidation, other business combination or otherwise, of greater than 50% of the total voting power (on a fully diluted basis as if
all convertible securities had been converted and all warrants and options had been exercised) entitled to vote in the election of directors of the Company (including any transaction in which the Company becomes a wholly-owned or majority-owned
subsidiary of another corporation), or 
 (ii) any merger or consolidation or reorganization in which the Company does not
survive, or 
 (iii) any merger or consolidation in which the Company survives, but the shares of the Company’s Common Stock outstanding immediately
prior to such merger or consolidation represent 50% or less of the voting power of the Company after such merger or consolidation, or 
 (iv) any transaction in which more than 50% of the Company’s assets are sold. 
 However, no transaction contemplated by
clauses (i) through (iv) above shall constitute a Change of Control if both (x) the person acting as the Chief Executive Officer of the Company for the six months prior to such transaction becomes the Chief Executive Officer or
Executive Chairman of the Board of Directors of the entity that has acquired control of the Company as a result of such transaction (the “Acquiror”) immediately after such transaction and remains the Chief Executive Officer or Executive
Chairman of the Board of Directors for not less than one year following the transaction and (y) a majority of the Acquiror’s board of directors immediately after such transaction consist of persons who were directors of the Company
immediately prior to such transaction. For purposes of this Agreement, “Cause” means: (1) a material breach by you of your duties and responsibilities which do not differ in any material respect from your duties and responsibilities
during the ninety (90) day period immediately prior to a Change in Control (other than as a result of incapacity due to physical or mental illness) which is demonstrably willful and deliberate on your part, which is committed in bad faith or
without reasonable belief that such breach is in the best interests of the Company and which is not remedied in a reasonable period of time after receipt of written notice from the Company specifying such breach; (2) willful misconduct or gross
negligence which results in material harm to the Company; or (3) your conviction of, or a plea of nolo contendere by you to, a felony or other crime involving fraud or dishonesty; or (4) willful violation of Company policies which
results in material harm to the Company.Form of Stock Appreciation Rights Agreement-Employee (2002 Plan)

 Exhibit 10.4 
 Form of Stock Appreciation Rights Agreement under 
 the DaVita Inc. 2002 Equity Compensation Plan

 - Employee 
 Primary Terms

  

			
	Grantee:	  	
		
	SSN:	  	
		
	Address:	  	
		  	
		  	
		
	Grant Date:	  	
		
	Base Shares:	  	
		
	Base Price per Share:	  	
		
	Expiration Date:	  	
		
	Plan Name:	  	2002 Equity Compensation Plan
		
	Plan ID#:	  	2002
		
	Vesting Schedule:	  	

 The terms set forth above, together with the terms and conditions attached, constitute one agreement.

 Note: Please mark and initial any correction to the Name, SSN and/or Address shown on this page before returning a signed copy of this agreement to
the Stock Plan Administrator. 

 This Stock Appreciation Rights Agreement is dated as of
                     (“Grant Date”) by and between DaVita Inc., a Delaware corporation (“Company”) and
                     (“Grantee”) pursuant to the Company’s 2002 Equity Compensation Plan (“Plan”).
Capitalized terms that are used but not defined in this document shall have the meanings set forth in the Plan. 
 1. Grant of SAR.

 The Company hereby grants to the Grantee the right (“SAR”) to receive with respect to all or any portion of
                 shares (“Base Shares”) of the common stock of the Company (“Common Stock”) a number of shares (“Gain
Shares”) of Common Stock with a Fair Market Value equal to the amount by which the Fair Market Value of one share of Common Stock on the date on which the SAR is exercised exceeds a base price of
$                 per share (“Base Price”).  
 2. Term of SAR. 
 (a) This SAR shall be effective for the period
(“Term”) from the Grant Date shown above through July 1, 2011 (“Expiration Date”). 
 (b) In the
case of the termination of the Grantee’s employment with the Company (“Severance”), the following rules shall apply in determining the date on which the SAR shall terminate. 
 (i) If the Grantee dies while employed by the Company or during the three (3) month period immediately subsequent to his or her
Severance, the SAR shall terminate one (1) year from the date of the Severance. 
 (ii) If the Grantee was disabled
(within the meaning of Section 22(e)(3) of the Code) at the time of his or her Severance, the SAR shall terminate one (1) year following the Severance. 
 (iii) In all other cases, the SAR shall terminate three (3) months following the Severance. 
 (c) If the Grantee is transferred between the Company and a subsidiary thereof, or vice versa, or between subsidiaries, Severance
shall not be deemed to have occurred. 
 (d) If there is a meaningful reduction, determined in the Company’s sole
discretion, in both the Grantee’s duties and responsibilities and the level of the Grantee’s regular cash compensation for an extended or indefinite period of time, the Company reserves the right to unilaterally revoke some or all of the
unvested portion of the SAR. 
 3. Exerciseability. 
 (a) The Base Shares subject to this SAR shall become exerciseable (“vest”) on the dates indicated under the Vesting Schedule
table above such that this SAR shall be fully exerciseable on the last date listed on such table; provided, however, that such vesting shall cease at the time of Grantee’s Severance. 
 (b) These installments shall be cumulative, so that this SAR may be exercised as to any or all of the Base Shares covered by an
installment at any time or times after the installment becomes vested and until this SAR terminates. 
 (c) The foregoing
notwithstanding, in the event that either (i) in connection with a “Change of Control” (defined below), the “Acquiror” (defined below) fails to assume, convert or replace this SAR, or (ii) the Grantee’s employment
is terminated within the twenty-four (24) month period following a Change of Control by the Company (or the Acquiror) other than for “Cause” (defined below) or, if applicable, by the Grantee in accordance with the termination for
“Good Reason” provisions of the Grantee’s employment agreement, if any, then, in any such case, this SAR shall automatically vest and become immediately exerciseable in its entirety, such vesting to be effective as of immediately
prior to the effective date of the Change of Control in the case of (i), and as of the date of termination of the Grantee’s employment in the case of (ii). For purposes of this agreement, a “Change of Control”, is defined herein as
(i) any transaction or series of transactions in which any person or group (within the meaning of Rule 13d-5 under the Exchange Act and Sections 13(d) and 14(d) under the Exchange Act) becomes the direct or indirect “beneficial owner”
(as defined in Rule 13d-3 under the Exchange Act), by way of a stock issuance, tender offer, merger, consolidation, other business combination or otherwise, of greater than 50% of the total voting power (on a fully diluted basis as if all
convertible securities had been converted and all warrants and options had 

 
been exercised) entitled to vote in the election of directors of the Company (including any transaction in which the Company becomes a wholly-owned or
majority-owned subsidiary of another corporation), or (ii) any merger or consolidation or reorganization in which the Company does not survive, or (iii) any merger or consolidation in which the Company survives, but the shares of the
Company’s Common Stock outstanding immediately prior to such merger or consolidation represent 50% or less of the voting power of the Company after such merger or consolidation, or (iv) any transaction in which more than 50% of the
Company’s assets are sold, provided, however, that no transaction contemplated by clauses (i) through (iv) above shall constitute a Change of Control if both (x) the person acting as the Chief Executive Officer of the Company for
the six months prior to such transaction becomes the Chief Executive Officer or Executive Chairman of the Board of Directors of the entity that has acquired control of the Company as a result of such transaction (the “Acquiror”)
immediately after such transaction and remains the Chief Executive Officer or Executive Chairman of the Board of Directors for not less than one year following the transaction and (y) a majority of the Acquiror’s board of directors
immediately after such transaction consist of persons who were directors of the Company immediately prior to such transaction. For purposes of this Agreement, “Cause” means: (1) a material breach by the Grantee of those duties and
responsibilities of the Grantee which do not differ in any material respect from the duties and responsibilities of the Grantee during the ninety (90) day period immediately prior to a Change in Control (other than as a result of incapacity due
to physical or mental illness) which is demonstrably willful and deliberate on the Grantee’s part, which is committed in bad faith or without reasonable belief that such breach is in the best interests of the Company and which is not remedied
in a reasonable period of time after receipt of written notice from the Company specifying such breach; (2) willful misconduct or gross negligence which results in material harm to the Company; or (3) the conviction of the Grantee of, or a
plea of nolo contendere by the Grantee to, a felony or other crime involving fraud or dishonesty; or (4) willful violation of Company policies which results in material harm to the Company. 
 (d) Except as otherwise provided for herein, the Grantee’s Severance (whether by reason of death or otherwise) shall not accelerate
the number of Base Shares with respect to which an SAR may be exercised. 
 4. Method of Exercising. 
 This SAR may be exercised by the Grantee upon delivery of the following documents to the Company at its principal executive offices, or as
otherwise required in accordance with a broker-assisted cashless exercise program: 
 (a) Written notice, in the form of a
completed exercise election form, specifying the number of Base Shares with respect to which the SAR is being exercised; 
 (b) Such agreements or undertakings that are required by the Committee pursuant to the Plan; and 
 (c) Provision for the payment of any taxes (including withholding taxes) which may be required by the Committee. 
 5.
Settlement of SAR. 
 Upon exercise of the SAR, in whole or in part, the Company shall: 
 (1) provide for the registration in book-entry form for the Grantee’s benefit of the Gain Shares (rounded down to the nearest whole
number, and which may be reduced by any Gain Shares required to be withheld or sold on behalf of the Grantee to satisfy tax withholding requirements), or 
 (2) deliver to the Grantee a stock certificate representing the Gain Shares (rounded down to the nearest whole number, and which may be reduced by any Gain Shares required to be withheld or sold on behalf of the
Grantee to satisfy tax withholding requirements). 
 6. Assignments.  
 (a) This SAR shall be exerciseable only by the Grantee during the Grantee’s lifetime. 

 (b) The rights of the Grantee under this SAR may not be assigned or transferred except by
will or by the laws of descent and distribution. 
 7. No Rights as a Stockholder.  
 The Grantee shall have no rights as a stockholder of any Base Shares or Gain Shares unless and until Gain Shares are issued to Grantee
upon the exercise of the SAR. 
 8. Interpretation of SAR. 
 (a) This SAR is granted under the provisions of the Plan and shall be interpreted in a manner consistent with it. 
 (b) Any provision in this SAR inconsistent with the Plan shall be superseded and governed by the Plan. 
 (c) For all purposes under this SAR, employment by the Company shall include employment by the Company or any subsidiary thereof.

 9. Legends on Certificates. 
 The Grantee acknowledges that the certificates representing any Gain Shares issued upon exercise of this SAR may bear such legends and be subject to such restrictions on transfer as the Company may deem necessary to
comply with all applicable state and federal securities laws and regulations. 
 10. Amendments. 
 This SAR may be amended at any time with the consent of the Company and the Grantee. 
 11. Non-Competition/Non-Solicitation/Non-Disclosure. 
 (a) The Grantee acknowledges and recognizes the highly competitive nature of the business of the Company and accordingly agrees that while
Grantee is an employee of the Company and for the one-year period following termination of such relationship, the Grantee will not (i) engage in or become an employee, director, principal or shareholder of, consultant to or equity participant
in, any person, firm, partnership, joint venture, association, corporation or other business organization, entity or enterprise other than the Company that engages in activities that are in competition with the Company in the United States (the
“Territory”); (ii) directly or indirectly, own, manage, control, operate, invest in, acquire an interest in, or otherwise engage in, act for, or act on behalf of any person firm, partnership, joint venture, association, corporation or
other business organization, entity, or enterprise other than the Company that engages in activities that are in competition with the Company; (iii) be an officer, director, consultant, partner, employee, creditor, agent, trustee, independent
contractor, or advisor on a paid or unpaid basis of any person, firm, partnership, joint venture, association, corporation or other business organization, entity, or enterprise that has been a supplier to or client of the Company; (iv) be an
officer, director, consultant, partner, owner, employee, creditor, agent, trustee, independent contractor, or advisor on a paid or unpaid basis of any physician group or physician partners who provide nephrology-related services;
(v) (x) directly or indirectly induce any employee of the Company, its affiliates or its subsidiaries or any physician with privileges at a dialysis facility owned by the Company, its affiliates or its subsidiaries to (A) engage in
any activity that Grantee has agreed to refrain from pursuant to (i)-(iv) above or (B) terminate his or her relationship with the Company or any of its affiliates or subsidiaries or (y) directly or indirectly employ, or offer
employment to or other similar arrangement with, any person who is or was during the period of the Grantee’s employment or consulting or advisory relationship with the Company, or was beforehand, employed or engaged by the Company, its
affiliates or subsidiaries, including but not limited to a medical director of a dialysis facility owned or operated by the Company, its subsidiaries or affiliates, or a physician with admitting privileges at a dialysis facility owned, operated or
managed by Company, or one of its affiliates or subsidiaries, or (vi) take any action that results, or might reasonably result in any of the foregoing. 
 (b) In addition, Grantee agrees not to disclose or use for his or her own benefit or purposes or for the benefit or purposes of any
person, firm, partnership, joint venture, association, corporation or other business organization, entity or enterprise other than the Company and any of its subsidiaries or affiliates, any trade secrets, information, data, or other confidential
information relating to customers, development, programs, costs, marketing, trading, investment, sales activities, promotion, credit and financial data, financing methods, plans, or the business and affairs of the Company (“Information”);
provided, however, the foregoing shall not apply to (i) Information which is not unique to the Company, or (ii) Information 

 
which is generally known to the industry or the public other than as a result of the Grantee’s breach of this covenant, or (iii) disclosure that is
required by any applicable law, rule or regulation. If Grantee receives such a request to produce Information in his or her possession, Grantee shall provide Company reasonable advance notice, in writing, prior to producing said Information, so as
to give Company reasonable time to object to Grantee producing said Information. Grantee also agrees that Grantee will not become employed by or enter into service with any person, firm, partnership, joint venture, association, corporation or other
business organization, entity or enterprise other than the Company and any of its subsidiaries or affiliates in which Grantee will be obligated to disclose or use any Information, or where such disclosure would be inevitable because of the nature of
the position. 
 (c) If, at any time within (a) the Term of this SAR, or (b) one (1) year after
termination of employment for any reason, whichever is the latest, Grantee (i) breaches the non-competition provision of Section 11(a), (ii) breaches the non-solicitation provision of Section 11(a), (iii) breaches the
non-disclosure provision of Section 11(b), (iv) is convicted of a felony, (v) has been adjudicated by a court of competent jurisdiction of having committed an act of fraud or dishonesty resulting or intending to result directly or
indirectly in personal enrichment at the expense of the Company, or (vi) is excluded from participating in any federal health care program, then (1) this SAR shall terminate effective on the date on which Grantee enters into such activity
and (2) any gain realized by Grantee from exercising all or a portion of this SAR shall be paid by Grantee to the Company. 
 This
agreement may be considered null and void at the discretion of the Company if a signed copy is not returned to the Stock Plan Administrator for the Company by NO LATER THAN
                        , 2006. 
 In Witness Whereof, the Company and the Grantee have executed this SAR effective as of the date first written above. 
  

									
	 Grantee
	 	 	 	 Leadership
 (Executive, V.P., etc.)
	 	 	 	 Company

					
	  
 Printed Name
	 		 	  
 Printed Name
	 		 	  
 Printed Name

					
	  
 Signature
	 		 	  
 Signature
	 		 	  
 Signature

					
	  
 Title
	 		 	  
 Title
	 		 	  
 Title

					
	  
  
 Division/Department
	 		 	  
 Division/Department
	 		 	  
 Division/Department

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}]]